Outlook Therapeutics Inc (OTLK)

[H2R]

Upcoming Milestones / PR 2022-02-14

* Planned submission of new BLA to the FDA in the first calendar quarter of 2022;

* Ongoing pre-launch commercial planning underway in anticipation of potential approval for ONS-5010 within the next 12 months;

* Completion of the NORSE SEVEN study evaluating Outlook Therapeutics’ vial delivery system versus a pre-filled syringe of ONS-5010 in calendar 2022; and

* Continued preparation for NORSE FOUR (BRVO) and NORSE FIVE and NORSE SIX (DME) evaluating ONS-5010 for additional ophthalmic indications in calendar 2023.

https://seekingalpha.com/pr/18669894-outlook-therapeutics-reports-financial-results-for-first-quarter-fiscal-year-2022-and

Executing on the plan.

Best of luck with your investments!